Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261480 | 0.85 | AHR (0.31) | — | |
| SCHEMBL261482 | 0.84 | KDM4E (0.31) | — | |
| SCHEMBL13282082 | 0.81 | KMT2A (0.35) | KMT2ASMN1; SMN2CALCRL | |
| SCHEMBL261526 | 0.81 | KMT2A (0.35) | KMT2ASMN1; SMN2CALCRL | |
| SCHEMBL261150 | 0.76 | CALCRL (0.45) | KMT2ACALCRL | |
| SCHEMBL261152 | 0.75 | CALCRL (0.35) | CALCRL | |
| SCHEMBL261453 | 0.74 | CALCRL (0.46) | KMT2ASMN1; SMN2CALCRL | |
| SCHEMBL261544 | 0.70 | CALCRL (0.32) | CALCRL | |
| SCHEMBL261539 | 0.66 | — | — | |
| SCHEMBL13253749 | 0.65 | DAO (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794146-B1 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | C1R, CALCB, MRGPRX2 | KMT2A 4485/4885SMN1; SMN2 4505/4885CALCRL 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.